Autostimulatory growth factors produced by Sjögren's syndrome B cell lines.

Clin Immunol Immunopathol

Clinical Immunology Section, Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas.

Published: October 1989

Sjögren's syndrome (SS) is a systemic autoimmune disorder characterized by polyclonal hypergammaglobulinemia, autoantibody formation, and intense tissue infiltration by lymphoid and plasma cells. These patients have a predisposition to the development of monoclonal immunoglobulins and B cell lymphomas. To study the role of B cells in this disease, we established B cell lines from three patients with benign primary SS. These B cell lines grew spontaneously without any stimulation and expressed EBV nuclear antigen. The lines secreted an autostimulatory factor which had properties of a B cell growth factor. Peripheral blood B cells from SS patients, after culture for 3 days, secreted a similar factor which stimulated the proliferation of established SS B cell lines. These results suggest that circulating B cells in SS produce an autocrine growth factor that may contribute to lymphoproliferation and ultimately to the emergence of B cell lymphomas.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0090-1229(89)90107-4DOI Listing

Publication Analysis

Top Keywords

cell lines
16
sjögren's syndrome
8
cells patients
8
cell lymphomas
8
established cell
8
growth factor
8
cell
7
lines
5
autostimulatory growth
4
growth factors
4

Similar Publications

Target cyclooxygenase 2 (COX-2) and 5-lipoxygenase (5-LOX) inhibitors; 5-([2,5-Dihydroxybenzyl]amino)salicylamides (Compounds 1-11) were examined for potential anticancer activity, with a trial to assess the underlying possible mechanisms. Compounds were assessed at a single dose against 60 cancer cell lines panel and those with the highest activity were tested in the five-dose assay. COMPARE analysis was conducted to explore potential mechanisms underlying their biological activity.

View Article and Find Full Text PDF

The epithelial-mesenchymal transition (EMT) assists in the acquisition of invasiveness, relapse, and resistance in non-small cell lung cancer (NSCLC) and can be caused by the signaling of transforming growth factor-β1 (TGF-β1) through Smad-mediated or Smad-independent pathways. (-)-Epigallocatechin-3-gallate (EGCG), a multifunctional cancer-preventing bioconstituent found in tea polyphenols, has been shown to repress TGF-β1-triggered EMT in the human NSCLC A549 cell line by inhibiting the activation of Smad2 and Erk1/2 or reducing the acetylation of Smad2 and Smad3. However, its impact on the Smad-independent pathway remains unclear.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) is one of the most common and highly lethal cancers worldwide. RIO kinase 1 (RIOK1), a protein kinase/ATPase that plays a key role in regulating translation and ribosome assembly, is associated with a variety of malignant tumors. However, the role of RIOK1 in HCC remains largely unknown.

View Article and Find Full Text PDF

Introduction: Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.

Methods: Between 12/2019 and 06/2022, 237 patients were included.

View Article and Find Full Text PDF

Increasing demand for adeno-associated virus (AAV) used in gene therapy highlights the need to enhance AAV production. When intracellular AAV2 and extracellular AAV9 were produced in HEK293T cells using the triple transfection method, apoptosis occurred during the AAV production. To mitigate apoptosis induced by AAV production, the pro-apoptotic BAX/BAK1 genes were knocked out in HEK293T cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!